Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Hospital Stocks Won't Profit From More Coronavirus Cases

By Adria Cimino - Mar 19, 2020 at 6:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As COVID-19 patients seek treatment, hospitals may have to cancel some of their most lucrative procedures.

As coronavirus cases reach more than 1,700 in the U.S., and the pandemic escalates worldwide, investors might wonder if hospital stocks will benefit from the influx of patients. So far, stocks such as HCA Healthcare (HCA -4.51%) and Universal Health Services (UHS -5.15%) have not. The hospital operators have each posted a decline of about 43% this year, and that downward pressure is likely to continue as hospitals limit more expensive procedures -- and face unexpected costs -- to ensure coronavirus care.

A group of doctors discuss the coronavirus outbreak outside a hospital.

Image source: Getty Images.

Hospitals have already begun postponing elective surgeries to prepare for patients suffering from COVID-19, the illness caused by the new coronavirus. Last week, the American College of Surgeons recommended minimizing, postponing, or cancelling elective procedures until the outbreak is considered manageable by healthcare facilities. That was reinforced by U.S. surgeon general Dr. Jerome M. Adams in a message on Twitter.

Contribution to revenue

The postponement or cancellation of elective surgeries is bad news for hospitals, considering those procedures' contribution to revenue. According to Kaiser Health News, hospitals make about $700 more on an elective admission compared with an admission to the emergency room.

Other statistics point to the importance of surgical procedures for a hospital's revenue. An Agency for Healthcare Research and Quality report showed that stays involving surgery represented about 48% of 2011 hospitalization costs. Surgeons are the top sources of revenue among hospital doctors, with cardiovascular surgeons bringing in the most for their hospitals, according to a Merritt Hawkins survey. Orthopedic surgeons, who often perform elective procedures like knee arthroscopy or carpal tunnel release, generated $3.3 million for their hospitals annually, for the fourth spot in the ranking.

The American Hospital Association and other organizations sent a letter to the surgeon general on Sunday after the recommendations to halt elective surgeries. They expressed concern, indicating that some procedures must be prioritized to meet the needs of seriously ill patients. What will actually happen once the crisis deepens remains to be seen.

Higher costs

Aside from the problem of canceling procedures, hospitals face the challenge of managing the influx of COVID-19 patients. In a note last month, Moody's said that if the outbreak deepened, hospitals may face higher costs. While losing revenue through the cancellation of more expensive procedures, hospitals might simultaneously have to hire contract workers to handle increasing urgent-care demand, according to the report.

These problems are compounded by other challenges. The American Hospital Association showed underpayments by Medicare and Medicaid to U.S. hospitals totaled more than $76 billion in 2018. Hospitals received 87 cents and 89 cents for Medicare and Medicaid patients, respectively, for every dollar they spent to care for those patients, the report showed. While hospitals with outpatient services may benefit to a certain degree from these procedures, they and their smaller peers still face the challenge of fewer or shorter hospital stays. Outpatient visits and surgeries have grown steadily from 1995 through 2016, according to American Hospital Association data.

At the same time, hospital shares, like the rest of the market, have taken a hit as the coronavirus expanded from outbreak to pandemic. HCA Healthcare and Universal Health are both trading at their cheapest in relation to earnings since 2012. During its last earnings report, HCA Healthcare predicted 2020 full-year revenue may gain as much as 8% to reach $55.5 billion. Universal Health's guidance indicated 2020 revenue could increase as much as 6.1% to $12.1 billion. Both companies have reported revenue increases for at least the past three years.

More weakness ahead

HCA Healthcare, Universal Health, and peers may face headwinds in the coming weeks as the coronavirus outbreak plays out -- and resulting costs could weigh on the current quarter's earnings. That means more share-price weakness ahead.

For the long term, however, the story is brighter. Both HCA Healthcare and Universal Health are major players in the industry with a track record of growing revenue, and both should bounce back. Healthcare investors should keep an eye on the progression of the coronavirus outbreak and add both stocks to their watchlists. Once we have an idea of how long hospitals will be submerged in this crisis, we can start to make buying decisions.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Universal Health Services, Inc. Stock Quote
Universal Health Services, Inc.
$120.92 (-5.15%) $-6.56
HCA Healthcare, Inc. Stock Quote
HCA Healthcare, Inc.
$206.22 (-4.51%) $-9.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.